

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 39/108</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/05326</b> <b>(43) International Publication Date:</b> 17 March 1994 (17.03.94)
<b>(21) International Application Number:</b> PCT/CA93/00365 <b>(22) International Filing Date:</b> 3 September 1993 (03.09.93)  <b>(30) Priority data:</b> 939,496 4 September 1992 (04.09.92) US 08/115,683 3 September 1993 (03.09.93) US  <b>(71) Applicant:</b> UNIVERSITY OF SASKATCHEWAN [CA/CA]; 124 Veterinary Road, Saskatoon, Saskatchewan S7N 0W0 (CA).  <b>(72) Inventors:</b> ALLAN, Brenda, J. ; 12 Oliver Crescent, Saskatoon, Saskatchewan S7H 3C8 (CA). POTTER, Andrew, A. ; 521 Dalhousie Crescent, Saskatoon, Saskatchewan S7H 3S5 (CA).		<b>(74) Agent:</b> GRAY, Brian, W.; Blake, Cassels & Graydon, Box 25, Commerce Court West, Toronto, Ontario M5L 1A9 (CA).  <b>(81) Designated States:</b> AU, CA, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> NOVEL BACTERIAL VACCINES USING VACCINE STRAINS OF PATHOGENIC BACTERIA  <b>(57) Abstract</b>  Vaccines are provided for vaccinating an animal against pathogenic bacteria, including <i>E. coli</i> . The invention also encompasses methods of preparing and methods of use of vaccine strains and compositions that result from or are used in these methods.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

-1-

NOVEL BACTERIAL VACCINES  
USING VACCINE STRAINS OF  
PATHOGENIC BACTERIA

Field of the Invention

- 5           The present invention relates to vaccines against pathogenic bacteria.

References

10           The following references are cited in this application as superscript numbers at the relevant portions of the application.

1. Aitken et al., *Vaccine*, 10:271 (1992).
2. Bouvier et al., *Proc. Nat'l. Acad. Sci. USA*, 81:4139-4143 (1984).
- 15 3. Cheville et al., *J. Am. Vet. Med. Assoc.*, 173:584-587 (1978).
4. Dozois et al., *Infection and Immunity*, July 1992:2648-2656 (1992).
5. Fairweather et al., *Res. Microbiol.*, 141:769-773 (1990).
- 20 6. Fontaine et al., *Res. Microbiol.*, 141:907-912 (1990).
7. Gross, *Diseases of Poultry*, 9th Ed.:138-144 (1991).
- 25 8. Curtiss III et al., *Infection and Immunity*, 55:3035-3043 (1987).
9. Hormaeche et al., *Res. Microbiol.*, 141:757-764 (1990).
10. Jones et al., *Vaccine*, 10:280 (1992).
- 30 11. Lafont et al., *Infection and Immunity*, Jan. 1987:193-197 (1987).
12. Leitner et al., *Avian Dis.*, 36:211-220 (1992).

-2-

13. Meister, *Adv. Enz.*, **62**:315-374 (1989).
14. Mergeay et al., *Molec. Gen. Genet.*, **133**:299-316 (1974).
- 5 15. Miller et al., *Res. Microbiol.*, **141**:817-821 (1990).
16. Moon, *Vaccine*, **10**:269 (1992).
17. Nakamura et al., *Vet. Pathol.*, **2**:592-597 (1985).
18. Nyunoya et al., *Proc. Nat'l. Acad. Sci. USA*, **80**:4629-4633 (1983).
- 10 19. Nyunoya et al., *J. Biol. Chem.*, **259**:9790-9798 (1984).
20. Piette et al., *Proc. Nat'l. Acad. Sci. USA*, **81**:4134-4138 (1984).
21. Sternberg et al., *Methods Enz.*, **204**:18-28 (1991).
- 15 22. Stocker, U.S. Patent No. 5,077,044 (1991).
23. Trotta et al., *Proc. Nat. Acad. Sci. USA*, **68**:2599-2603 (1971).
24. Vidotto et al., *Avian Dis.*, **34**:531-538 (1990).
25. Ron, U.S. Patent No. 4,404,186 (1983).
- 20 26. Kunkel, *Proc. Nat'l. Acad. Sci. USA*, **82**:488-492 (1985).
27. Sambrook et al., *Molecular Cloning*, 2nd Ed.:1.5, 1.74 and 1.75 (1989).
28. Stocker, U.S. Patent No. 5,210,035 (1993).
- 25 29. Emery et al., *North Central Avian Diseased Conference*, 23-34 (1988).
30. Griffin et al., *Vaccine*, **11**:457-462 (1993).
31. Nagaraja et al., *International Publication No. WO92/12732* (1992).
- 30 32. Bagg et al., *J. Bact.*, **161**:457-462 (1993).
33. Hantke, *FEMS Micro. Letters*, **15**:83-86 (1982).
34. Hantke, *Mol. Gen. Genet.*, **182**:288-292 (1991).

-3-

35. Webster, *Mol. Microbiol.*, 5:1005-1011 (1991).
36. Wandersman et al., *Proc. Nat'l. Acad. Sci. USA*, 87:4776-4780 (1990).
37. Davies et al., *J. Bact.*, 123:102-117 (1975).
- 5 38. Leyh et al., *Am. J. Vet. Res.*, 49:687-692 (1988).
39. Heesemann et al., 93rd Gen. Mtg. of A.S.M., Abstract B-295 (1993).
40. Rioux et al., *Anal. Biochem.*, 133:163-169 (1983).
- 10 41. Fields et al., *Proc. Nat'l. Acad. Sci. USA*, 83:5189-5193 (1986).
42. Kleckner, *Cell*, 16:711-720 (1979).
43. Halling et al., *Proc. Nat'l. Acad. Sci. USA*, 79:2608-2612 (1982).
- 15 44. Bender et al., *Proc. Nat'l. Acad. Sci. USA*, 89:7996-8000 (1992).

The disclosures of the above publications and patents are herein incorporated by reference in their entirety to the same extent as if the language of each individual publication or patent were specifically and  
20 individually included herein.

#### BACKGROUND OF THE INVENTION

Vaccination with live attenuated strains is extensively and successfully used in the prevention of various viral diseases of man, such as polio and  
25 smallpox. However, there are only a few such vaccines effective against bacterial diseases of man or domestic animals; BCG vaccine for prevention of tuberculosis, strain 19 vaccine against bovine brucellosis and Sterne's spore vaccine against anthrax in cattle are  
30 well-known examples.

-4-

Use of live vaccines is hampered by a number of factors. Some strains considered for use as live vaccines retain an unacceptable degree of virulence, by reversion or otherwise. Some live vaccines display short persistence of immunity attributed to early disappearance of the vaccine strain from host tissues and, in some instances, incomplete immunity so that some vaccinated animals die after challenge with a virulent strain.

10       The non-virulent strains used as vaccines have been obtained in various ways. The BCG strain was derived by empirical procedures during prolonged in vitro cultivation, and probably owes its non-virulence to multiple unidentified mutations. Sterne's *Bacillus anthracis* spore vaccine is a strain which has lost the ability to synthesize the polypeptide capsule, important as a determinant of virulence but not as a "protective" antigen. Some experimenters have used as live vaccine merely a sublethal dose of a "wild" strain of relatively low virulence in the sense that the LD50 was a large number of bacteria -- a situation in which there is evident risk of severe or fatal infection developing in some vaccinated subjects and of transmission to other hosts.

25       Since live vaccines have substantially greater probability of success in providing protection for the host against a subsequent invasion of a virulent wild strain than killed vaccines or subunit vaccines, it is desirable to develop new live vaccines which avoid the shortcomings of vaccines prepared previously. Because the immune response of the vertebrate host to antigens, in particular surface antigens, of the pathogenic microorganism is the basic mechanism of protection by vaccination, a live vaccine should retain the antigenic



-5-

complement of the wildtype strain. The live vaccine should be non-virulent and substantially incapable of sustained multiplication in the host.

Several live attenuated *Salmonella* vaccines have recently been developed for intracellular pathogenic *Salmonella*. These include mutant *aroA* strains<sup>9,10</sup>, strains with mutations in the *phoP* virulence region<sup>15</sup>,  $\Delta$ *cydA* $\Delta$ *crp* *S. typhimurium*<sup>8</sup>, and *aroA**aroC* mutants<sup>5</sup>. Purine mutations were found to be too attenuating for immunogenicity<sup>15</sup>. An *aroA* mutant was found to be ineffective against oral challenge when administered orally<sup>30</sup>.

Live attenuated vaccine strains of the intracellular pathogenic bacterial *Shigella flexneri* and *S. dysenteriae* have also been developed<sup>6</sup>. For example, novel non-reverting *Shigella* live vaccines prepared by producing auxotrophic mutants of a pathogenic strain are disclosed in U.S. Patent No. 5,077,044<sup>22, 28</sup>.

Vaccines developed for preventing *Escherichia coli* (hereinafter *E. coli*) infections include parenterally administered vaccines containing pilus antigens<sup>16</sup>, and orally administered vaccines containing recombinant enterotoxins<sup>1</sup>. Live vaccines using mutant non-pathogenic strains of *E. coli* have also been disclosed<sup>25</sup>. A temperature sensitive mutant *E. coli* produced using a chemical mutagen has been administered intravenously and orally<sup>29, 31</sup>.

*E. coli* infection in turkeys and chickens is manifested in several forms, the most common being colisepticemia, a respiratory disease characterized by airsacculitis, pericarditis, and perihepatitis<sup>7</sup>. This

-6-

disease is the leading cause of economic losses due to infectious disease to turkey producers in Canada and the United States of America. The primary site of colonization is the upper respiratory tract followed by extension into the lower respiratory tract. *E. coli* is generally inhaled by a contaminated litter dust and subsequently enters the bloodstream, probably via pulmonary lymphatics. Circulating bacteria are then trapped in sinusoids adjacent the central vein of the liver and in the marginal zones of periarteriolar reticular sheaths of the spleen. Such infections frequently develop as a secondary event subsequent to mycoplasma or viral infection. The most common primary viral agents are Newcastle disease virus and hemorrhagic enteritis virus (HEV). Thus, in order to be effective, a vaccine for *E. coli* should be proactive for such secondary infections as well as against primary challenge.

*E. coli* are commonly found in poultry houses. However, only certain isolates are able to cause disease, and these can be grouped by a technique called serotyping. The most common serotypes associated with disease in Canada and the United States of America are 01, 02 and 078<sup>3,17</sup>. Each serotype produces a number of virulence determinants which have been shown to induce protective immunity when incorporated in experimental vaccines. These include fimbriae (pili), appendages used by the bacteria to attach to host tissue, outer membrane proteins which are produced specifically to bind and use host nutrients for their growth, and toxins capable of impairing immune function. However, the delivery of these as vaccine components is usually by injection, a procedure not feasible in the field.

-7-

Studies of virulence determinants associated with *E. coli* isolated from colisepticemic chickens and turkeys showed that the presence of the aerobactin system, presence of adherence pili, and resistance to normal serum were associated with *E. coli* causing colisepticemia (in poultry) or lethality (in day-old chicks)<sup>4,24</sup>. Other characteristics present in virulent strains were invasion for HeLa and chicken fibroblast cells and colicin V<sup>24</sup>.

Despite advances in the field, there still exists a need for an effective, easily administered vaccine against infections from pathogenic bacteria, including *E. coli*.

#### SUMMARY OF THE INVENTION

Vaccines are provided for vaccinating an animal against pathogenic bacteria, including *E. coli*. The invention also encompasses methods of preparing and methods of use of vaccine strains and compositions that result from or are used in these methods.

Accordingly, in one aspect the invention provides vaccine strains of pathogenic bacteria comprising at least one mutation selected from the group consisting of a pyrimidine pathway mutation, an iron metabolism mutation, and a colicin transport mutation, said mutation providing attenuation of the virulence of said bacteria.

Another aspect of the invention provides a method of preparing a vaccine strain of a pathogenic bacteria comprising producing at least one mutation selected from the group consisting of a pyrimidine pathway mutation, an iron metabolism mutation, and a colicin

-8-

transport mutation in a virulent strain of said pathogenic bacteria to provide an attenuated organism; isolating the attenuated organism; and using it as a vaccine strain.

5           A further aspect of the invention provides a composition comprising at least one vaccine strain of a pathogenic bacteria comprising at least one attenuating mutation selected from the group consisting of a pyrimidine pathway mutation, an iron metabolism  
10           mutation and a colicin transport mutation.

          Yet another aspect of the invention is a method for preventing a bacterial disease in an animal comprising administering to the animal to be protected an effective amount of at least one vaccine strain of a  
15           pathogenic bacteria comprising at least one mutation selected from the group consisting of a pyrimidine pathway mutation, an iron metabolism mutation, and a colicin transport mutation.

#### DESCRIPTION OF THE INVENTION

##### 20    A.   Definitions

          As used herein the following terms have the following meanings:

          Antigen: refers to a molecule containing one or more epitopes that will stimulate a host's immune  
25           system to make a humoral and/or cellular antigen-specific response. For the purposes of this application, "antigen" and "immunogen" are used interchangeably.

-9-

Attenuation: diminution of virulence in a strain of an organism.

Bacterial disease: a disease caused by a bacteria, including those diseases which occur only in the presence of a predisposing viral infection or when the host is under stress.

carAB: the operon which codes for carbamoyl phosphatase. When used in [] following a serotype number, it denotes the presence of a carAB mutation in that organism.

Colicin transport-mutation: a mutation of one or more of the genes coding for proteins involved in the recognition and/or transport of macromolecules, as exemplified by colicin, into a bacterial cell.

Colisepticemia: disease caused by *E. coli* infection, including, but not limited to, cellulitis, air sacculitis and omphalitis. For the purposes of this application, "colisepticemia" and "colibacillosis" are used interchangeably.

Effective amount: dose required to induce an immune response sufficient to protect an animal against disease.

Extracellular pathogenic bacteria: a pathogenic bacteria which does not need to replicate within a host cell to cause disease.

fur: the gene which codes for the fur protein that functions as a global regulator in bacterial cells. When used in [] following a serotype number, it

-10-

denotes the presence of a fur mutation in that organism.

Immune response: development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest. Such a response usually consists of the subject producing antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells directed specifically to an antigen or antigens included in the composition or vaccine of interest.

Immunogenic: capable of inducing an immune response.

Intracellular pathogenic bacteria: a pathogenic bacteria which must replicate within a host cell to cause disease.

Iron metabolism mutation: a mutation of one or more of the genes coding for proteins involved in iron uptake, utilization, and/or regulation in a bacterial cell. For the purposes of this application, iron metabolism mutation includes modifications to any metabolic function regulated by one of these genes, whether or not this function is related to iron.

Morbidity: evidencing disease, including the presence of lesions in tissues.

Pathogenic: capable of causing disease.

Protective: capable of protecting an animal against disease.

-11-

Pyrimidine pathway mutation: a mutation of one or more of the genes coding for an enzyme involved in the pyrimidine pathway of a bacterial cell.

5 Stable mutant: a mutant with a low frequency of reversions. In general, mutants with reversion frequencies less than about  $10^{-7}$  are considered stable, with reversion frequencies less than  $1 \times 10^{-8}$  considered safe for vaccine strains.

10 tolC: the gene which codes for an outer membrane protein that is involved in colicin transport, hemolysin transport, and processing of other membrane proteins as well as partitioning of the chromosome. When used in [ ] following a serotype number, it denotes the presence of a tolC mutation in that organism.

15 Transduction: transfer of genetic material and its phenotypic expression from one cell to another by viral infection.

20 Vaccine strain: a normally virulent strain of bacteria which has been attenuated so that it no longer causes disease in the host, yet has the ability to induce an immune response in the host to protect the host from a virulent pathogenic strain. Vaccine strains may be live or killed. Killed vaccine strains may be preferred for in ovo inoculation or  
25 parenteral administration; live vaccine strains may be preferred for other forms of administration.

Virulent: capable of producing disease.

-12-

**B. Detailed Description of the Invention**

This invention provides vaccine strains of attenuated pathogenic bacteria. Preferred vaccine strains of this invention are mutants that have deletions, since these mutants should not revert. Particularly preferred vaccine strains of this invention include auxotrophic mutants having a pyrimidine pathway mutation causing a requirement in the strain for uracil, for example *carAB*, *pyrB*, *pyrC*, *pyrD* and *pyrE*. Also particularly preferred vaccine strains of this invention include mutants defective in iron metabolism, for example, *fur*, *fhuA* (or *tonA*), *fepA*, *cir* and *tonB*. Additional particularly preferred vaccine strains of the present invention include mutants with mutations in the colicin transport mechanism, for example *tolC*, *tolQ*, *tolR*, *tolA*, *tolB*, and *tolZ*. Most preferred live vaccine strains of this invention are auxotrophic mutants having a mutant *carAB* operon causing a requirement in the strains for both arginine and uracil. Also most preferred are mutants having a *fur* mutation which causes reduced synthesis of a protein involved in regulation of iron intake. Also most particularly preferred are mutants having a *tolC* mutation which prevents trans-location of colicins and appears to be required for hemolysin secretion<sup>36</sup>. Thus, the live vaccine strains of this invention, when introduced into the host, will continue to live and elicit a protective immune response, but will be unable to cause disease.

The use of a live vaccine strain having a mutation such that the bacterial strain requires the provision of more than one nutrient requirement reduces the chance that the host might inadvertently provide the necessary metabolites for replication of the bacteria.



-13-

Introduction of a second auxotrophic or other mutation into the live vaccine strain will further reduce the chance of reversion to wildtype.

It has been unexpected and surprising to find that  
5 pathogenic bacteria containing mutations in the  
pyrimidine pathway would be useful as live vaccine  
strains, in view of the fact that purine mutants were  
previously found to be too attenuated to be  
immunogenic<sup>15</sup>. It is likewise unexpected that mutations  
10 in the iron metabolism pathway would cause attenuation  
of pathogenic bacteria so as to make them useful in the  
vaccine strains of the present invention. Similarly,  
it is unexpected that colicin tolerant mutants would be  
attenuated. Thus, by applying the basic aspects of  
15 this invention as set forth herein, one skilled in the  
art will recognize the broad applicability of the  
present invention.

The methods of this invention for preparing  
20 vaccines, as well as the vaccines of this invention,  
have a large number of advantages over prior methods  
and vaccines. As contrasted with other vaccines, the  
subject invention provides for the exact cause of the  
loss of virulence. The subject strains should be able  
25 to persist in the host for extended periods of time,  
usually weeks, to enhance the effectiveness of the  
immunizing effect by continuous stimulation of the host  
immune system until the host immune system has cleared  
all the organisms. In view of the fact that the non-  
30 virulence does not depend on any host cellular  
function, the subject strains are expected to be non-  
virulent even in immunodeficient hosts.

The vaccines of this invention may be used with a  
wide variety of animals, as well as man. This includes

-14-

fish, birds, reptiles, avian species, and mammals. More particularly included are domestic animals which are treated by vaccines today or could be treated if susceptible to bacterial diseases, such as avian,  
5 leporine, bovine, porcine, equine, caprine, ovine or other animal species.

The mechanism and regulation of carbamoyl phosphate synthetase in *E. coli* has been extensively studied for many years<sup>2,13,23</sup>. This enzyme catalyzes the  
10 first reaction in pyrimidine and arginine biosynthesis, and is the product of the *carAB* operon. Numerous mutations of the *carAB* operon are known, some of which make *E. coli* not strictly auxotrophic for arginine and uracil<sup>14</sup>. The sequence of the two portions of the *carAB*  
15 operon, the *carA* gene and the *carB* gene are described in the literature<sup>18,19,20</sup>.

The mechanism and regulation of ferric iron transport in *E. coli* and *Salmonella typhimurium* has been studied<sup>32-34</sup>. Mutants defective in iron metabolism are  
20 constitutively derepressed for the synthesis of siderophores and their receptors. Recent studies of *fur* mutants in *Yersinia* showed that *fur* mutation had no effect on virulence<sup>39</sup>. Thus, it was unexpected to find that the *fur* mutants of the present inventions were  
25 attenuated.

The mechanism and regulation of macromolecule import into *E. coli* has been extensively studied for many years<sup>35-37</sup>. Bacteria carrying specific mutations which prevent binding of colicins have been termed  
30 colicin resistant. Mutations which allow normal binding of colicins, but do not allow translocation of the macromolecules to their target have been designated

-15-

colicin tolerant (tol). Numerous colicin resistant and colicin tolerant mutants are known<sup>37</sup>.

The particular mutation, for example the pyrimidine pathway mutation, the iron metabolism mutation, or the colicin transport mutation, may be introduced into pathogenic bacteria by means of conjugation, transformation, and/or phage-mediated transduction<sup>21,27</sup>. The particular method of introduction is not critical, and the preferred method may depend on the organism being transduced and the particular mutation to be introduced. These operons may be incorporated into many bacteria. This includes gram positive bacteria such as *Streptomyces* and *Bacillus* species. In particular, they may be introduced into any gram negative bacteria, and *Escherichia*, *Pseudomonas*, *Salmonella*, *Shigella* and *Yersinia* species are expected to be particularly useful in the present invention.

After transducing the pathogenic bacteria with the mutation, they are grown under conditions facilitating isolation of the mutants, either under conditions under which such mutants have a selective advantage over parental bacteria or under conditions allowing their easy recognition from unaltered bacteria or mutants of other types. The isolated mutants are cloned and screened for lack of virulence and ability to induce an immune response in a host to protect the host from a virulent pathogenic strain.

Among bacteria, the subject invention is particularly applicable to a wide variety of *E. coli* strains, more particularly serotypes 01, 02 and 078. Other pathogenic bacteria for which the subject invention may also be employed include, for example,

-16-

*Streptomyces, Bacillus, Salmonella, Shigella, Yersinia, Mycoplasma, Chlamydia, Streptococcus* and *Staphylococcus* species.

We have found that certain additional criteria may  
5 be used in selecting which pathogenic bacteria may be most useful as the vaccine strains of the present invention. Using these additional criteria allows better selections to be made. In particular it has been found that, especially with pyrimidine pathway  
10 mutations, extracellular pathogenic bacteria are preferred for use in the present invention. This may be due to the difference in available pyrimidine levels outside the host cells, e.g., in serum, as opposed to pyrimidine levels inside the cells of the host.

15 In preparing the live vaccine strains, one generally introduces a marker for distinguishing the auxotrophic mutant to be produced from other members of the strain into the vaccine strain. Various marker genes can be employed, such as resistance to antibiotic  
20 or synthetic antibacterial drugs, a block in a biosynthetic pathway causing a requirement for an amino acid or the like. The limitation on the particular marker is that it should not affect the immunogenic character of the microorganism, nor should it interfere  
25 with the processing of the microorganism to produce the live vaccine strain. The marker gene will alter the phenotype to allow for recognition of the subject microorganism.

30 Preferred pathogenic bacteria for use in the present invention will have stable mutations with few reversions. Frequencies of reversions less than about  $10^{-7}$  indicate stable mutations<sup>38</sup>. It has been found that many temperature sensitive mutants, especially those

-17-

which are uncharacterized, which effect DNA synthesis may be unsuitable for use as live vaccine strains due to the high frequency of reversions found in these mutants.

5           The use of a transducing phage, DNA-mediated transformation, and/or conjugation may also be employed to successively produce two or more independently mutated genes in a single host strain to be used as the vaccine strain. The presence of two completely  
10 independent mutations, each of which has an extremely low probability of reversion, provides almost absolute assurance that the vaccine strain cannot become virulent. In addition, each gene chosen will be  
15 involved in at least one, and preferably at least two, of the cellular functions of the bacteria such that the microorganism will be unable to multiply sufficiently to cause disease.

          This invention also provides vaccine strains of *E. coli* which contain one or more attenuating mutations.  
20 While a pyrimidine pathway mutation (such as the *carAB* mutation), an iron metabolism mutation (such as the *fur* mutation), or a colicin transport mutation (such as the *tolC* mutation) are preferred embodiments, attenuating mutations of *E. coli* useful in the present invention  
25 are not limited to these mutations. Other mutations of interest include mutations in the *groELES* operon, whose products function as chaperonins and assist in polypeptide folding and assembly; mutations in *htr* genes, which are required for growth at elevated  
30 temperatures but not at 30°C; and mutations in the *recA* gene, which is involved in general recombination and DNA damage repair.

-18-

*E. coli* vaccine strains of this invention are prepared generally as follows. An *E. coli* strain carrying the desired mutation is grown overnight, incubated with P1 phage, then grown again overnight on selected media containing chloramphenicol. *E. coli* lysogenic for P1 are isolated. A lysate is prepared by heat shocking the cells, then using chloroform to facilitate lysis. After centrifugation, the lysate is incubated with the *E. coli* strain to be transduced, then plated on selective media and incubated overnight. Isolates are tested to confirm that they contained the desired phenotype.

DNA-mediated transformation and/or conjugation may also be employed to produce one or more desired attenuating mutations in an *E. coli* strain to be used as the vaccine strain. Alternatively, an *E. coli* strain to be used as the vaccine strain may be treated with a chemical mutagen, such as nitrosoguanidine, or irradiated, such as with x-rays and the resulting attenuated mutants isolated according to the characteristics desired. Useful spontaneous mutations may also be isolated. Other methods which may be useful for producing mutants include site-directed mutagenesis<sup>26</sup> and restriction enzyme digestion and religation.

As discussed previously, the subject vaccines may be used in a wide variety of vertebrates. The subject vaccines will find particular use with man, domestic animals or other animals.

The manner of application of a vaccine strain of this invention may be varied widely, any of the conventional methods for administering a live vaccine being applicable. These include aerosol applications,

-19-

oral applications, in drinking water, on a solid physiologically acceptable base, or in a physiologically acceptable dispersion, parenterally (e.g., subcutaneously, intramuscularly, intravascularly, or intraperitoneally), by injection, by in ovo inoculation or the like. The dosage of the vaccine (number of bacteria, number of administrations, period of administration, etc.) will depend on route of administration and will vary according to the vaccine strain used and the species, age, and size of host to be protected. A person skilled in the art will be able to determine the dosage to be administered so as to provide a sufficient immune response.

The formulation of vaccine strain compositions may vary widely. Pharmaceutically acceptable vehicles, such as water, are expected to be useful for oral administration. Other pharmaceutically acceptable vehicles such as normal saline may be used for parenteral, cloacal or other routes of administration. The vaccine composition may also be admixed in the food for some applications.

The following examples are not intended to limit the scope of the invention in any manner.

#### C. Examples of Embodiments of the Invention

In general, the following materials and methods were used in these examples unless otherwise noted.

##### (1) Animal Model for Colisepticemia:

In order to test the feasibility of oral vaccination and the efficacy of the live vaccine strains of this invention, it was essential to

-20-

establish an experimental model of the disease. Since colisepticemia outbreaks in domestic fowl are often observed following hemorrhagic enteritis virus (HEV) infection, this model was based on challenge of HEV<sub>A</sub>-  
5 infected birds with *E. coli*. Similar models have been used by others to study colisepticemia in domestic fowl<sup>11,12</sup>.

Turkeys were obtained from Hybrid Turkeys, Inc., Kitchener, Ontario, Canada, as one-day-old poults.  
10 They were housed with access to water and turkey starter ration (Co-op Feeds) and treated in accordance with the guidelines established by the Canadian Council of Animal Care.

During challenge experiments, HEV<sub>A</sub> was delivered  
15 by oral administration to individual poults at seven weeks of age. The dose of HEV<sub>A</sub> used was 100 times the ED<sub>95</sub>. The ED<sub>95</sub> was defined as the dose that produced HEV<sub>A</sub> antigen in the spleens in 95% of 6-week old birds. *E. coli* was administered by three routes: (1)  
20 intravenous injection via a wing vein, (2) direct injection into the air sac with a small gauge needle, or (3) intratracheal injection between the tracheal rings with a small gauge needle. Vaccination of poults with *E. coli* was carried out at four weeks of age by  
25 oral administration to individual birds or via drinking water. Following HEV<sub>A</sub> and *E. coli* challenge, birds were examined daily for clinical signs of disease (bloody diarrhea, inappetence, arthritis), and seven days after bacterial challenge, all birds were  
30 sacrificed by cervical dislocation. Post mortems were carried out. Organ samples were cultured for *E. coli*, and the identity of all isolates was confirmed by biochemical tests.



-21-

(2) Development of Mutants of *E. coli*:

*E. coli* of serotype 01 (EC222), 02 (EC317) and 078 (EC234) were used as host strains. EC234 (serotype 078:K80:H9) is a field isolate obtained from Dr. L. Arp at Iowa State University, U.S.A. EC222 (serotype 01:H non-typeable) was isolated from the liver of a chicken broiler and was obtained from the Animal Health Division of Alberta Agriculture, Canada. EC317 (serotype 02:non-motile) was obtained from a diseased turkey and was provided by Dr. C. Riddell at the Western College of Veterinary Medicine, Saskatoon, Saskatchewan, Canada.

The source of *carAB* mutation was *E. coli* CGSC6181 (originally called NK6034; in our collection EC322). It was obtained from the *E. coli* Genetic Stock Center, Yale University, U.S.A. It was originally produced by N. Kleckner. It is *car96::Tn10*,  $\Delta(gpt-lac)5$ , *relA1*, *spoT1*, *thi-1*,  $\lambda^-$ .

The source of the *fur* gene was *E. coli* EC399, which is BN4020, obtained from Dr. Neiland, University of California, Berkeley, U.S.A. It is his *arg thi lac*  $\Delta$  U169 *galK fur::Tn5(Kn<sup>R</sup>)*.

The source of the *tolC* gene was *E. coli* EC532, which is GC7459, obtained from Dr. A. Jaffé, Institut Jacques Monod, Centre National de la Recherche Scientifique, Université Paris 7, 2 Place Jussieu, 75251 Paris Cedex 05, France. It is *tolC::Tn10*.

Generalized transducing phage Plcml, clr100 was obtained from Cold Springs Harbor Laboratory or M. Theisen of Veterinary Infections Disease Organization, Saskatoon, Saskatchewan, Canada. It is a mutant of

-22-

phage P1 that carries the genes for chloramphenicol resistance and is temperature sensitive. At 42°C clear plaques are produced while at 30°C turbid plaques are produced.

5           *E. coli* EC322, EC399, or EC532 was grown overnight at 37°C in LB + 5 mM CaCl<sub>2</sub>. To 0.5 mL of *E. coli* 25μL of P1 was added. After incubation at 30°C for 30 minutes 100 μL of this mixture was spread on each LB plate containing 12.5μL per mL of chloramphenicol. The  
10 plates were incubated at 30°C overnight. Colonies that grew were checked to be sure the strain was now temperature sensitive. (Strains lysogenic for this phage should not grow at 42°C.) LB plates containing chloramphenicol were prewarmed to 43°C and then  
15 inoculated with the strain that was putatively lysogenic for P1. To facilitate comparison with growth at 30°C a single colony was suspended in normal saline, and 100μL of this suspension was spread on a prewarmed plate (which was incubated at 42°C) and on an unwarmed  
20 plate (which was incubated at 30°C). After overnight incubation the growth on the plates was compared. Cultures that were temperature sensitive were stored at -70°C.

*E. coli* lysogenic for P1 was grown at 30°C in LB +  
25 10 mM MgSO<sub>4</sub> overnight. A 1:200 dilution from this culture was made into the same medium (50 mL in a 500 mL flask). The culture was incubated at 30°C with shaking until mid log phase (carAB) or an absorbance at OD<sub>660</sub> of 0.2 (fur and tolC) was reached. The culture was  
30 then shifted to 40°C (carAB) or 42°C (fur and tolC) and incubated for 40 minutes (carAB) or 20 minutes (fur and tolC) with aeration. The fur and tolC shift was done rapidly using a 42°C water bath. The culture was then transferred to 37°C and incubated for 1 to 2 hours.

-23-

- Partial lysis had occurred, and 5 mL of chloroform was added to facilitate lysis. After an additional 10 minutes at 37°C the culture debris was removed by centrifugation (10,000 rpm for 10 min in SS34 rotor).
- 5 The supernate was carefully transferred to a sterile screwtop tube containing 0.5 mL of chloroform. The lysate was stored at 4°C.

The strain to be transduced (EC234, EC222, EC317) was grown overnight in 5 mL of LB + 5 mM CaCl<sub>2</sub> at 37°C

10 with shaking.

For carAB, equal volumes of phage lysate and cells were mixed. The phage lysate was either used undiluted or diluted ten times. The mixtures were incubated at 30°C for 30 min and then plated on LB containing 5 or

15 10 µg/mL of tetracycline. The plates were incubated at 37°C or 42°C overnight. The bacterial colonies were picked and streaked on LB + tetracycline plates to check for purity.

For fur and tolC, the cells were pelleted by

20 centrifugation and resuspended in the original volume of 100 mM MgSO<sub>4</sub> and 5 mM CaCl<sub>2</sub>. The cells were aerated for 15 min at 37°C. Equal volumes of phage lysate and cells were mixed. The phage lysate was used either undiluted or diluted ten times. The mixtures were

25 incubated at 30°C for 30 min and then plated on LB containing 50 µg/mL of Kanamycin (fur) or LB containing 10 µg/mL of tetracycline (tolC). The plates were incubated at 37°C overnight. A few large colonies were seen on each plate and also a few pinpoint colonies.

30 The large bacterial colonies were picked and streaked on LB+Kanamycin plates (fur) or LB + tetracycline plates (tolC) to check for purity. These cultures were stored at 4°C until the phenotype could be confirmed.

-24-

These cultures were tested to confirm that they contained the correct (i.e., carAB, fur or tolC) phenotype.

To confirm the carAB phenotype, M9 salts agar (plus 0.2 or 0.5% casamino acids) was prepared and was supplemented with uracil (final concentration 20µg/mL). M9 salts medium will not support the growth of cultures containing the carAB mutation but will support the growth of the avian isolates of *E. coli* used. Supplementation with uracil allows the growth of isolates containing the carAB mutation. Strains that grow well on M9 salts agar with uracil but do not grow on M9 salts medium are considered to be carAB. Alternatively, M9 salts medium containing 50ng/mL nicotinic acid supplemented with uracil and arginine will support growth of bacteria containing carAB mutations, while the same medium without nicotinic acid will not support their growth.

To confirm the presence of the fur mutation, cultures were grown in LB or LB plus 200µM 2,2'-dipyridyl (DIP) at 37°C with shaking in 5 mL tubes for 20 hours. The absorbance at OD<sub>660</sub> was determined. The cells were pelleted using a bench top centrifuge and the pellet discarded. The supernates were stored at -20°C until the assays were done. The method of Rioux et al.<sup>40</sup> was used to determine the catechol siderophores in the supernates. Results were expressed as an absorbance ratio of OD<sub>510</sub>/OD<sub>660</sub>. These ratios were compared to that of the control wildtype strain. When the ratio of the mutants grown in iron rich medium was higher than that of the wildtype, the strains were used for further testing using outer membrane preparations. For outer membrane preparations cells were grown with or without DIP in LB to an absorbance OD<sub>660</sub> of about 1 to

-25-

2. Culture volume was 100 mL. Cells were harvested by centrifugation, washed twice with normal saline and stored at -20°C until used. Cells were resuspended in 5 mL Hepes buffer (10 mM, pH 7.4), transferred to a 15 mL tube and broken open by sonication. This material was transferred to a 37 mL tube (for the SS34 rotor) and centrifuged at 10,000 rpm for 10 minutes to remove debris. The supernate (usually 4 mL) was transferred to an oakridge tube for the type 50 rotor and 1.5 mL of 4% Sarkosyl (N-lauroylsarcosine, sodium salt) was added. This was incubated at room temperature for 30 min. The Sarkosyl insoluble fraction was pelleted by centrifuging in an ultracentrifuge for 1 hour, at 15 to 20°C at 35,000 rpm. The supernate was discarded. The small and clear to slightly turbid pellet was resuspended in 5 mL of 2% Sarkosyl using a disposable loop. It was then incubated for 30 min at room temperature and recentrifuged in an ultracentrifuge for 1 hour at 15 to 20°C at 35,000 rpm. This pellet was dissolved in 250 µL of Hepes buffer and stored at -20°C until used. Proteins were separated by discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (usually 10%) and stained with Coomassie brilliant blue. Mutants were identified as containing fur mutations based on their over production of catechols and iron-regulated outer membrane proteins in iron rich medium.

To confirm the tolC phenotype, isolates were selected for tetracycline resistance and inability to grow in LB containing 5 mg/mL of sodium dodecyl sulfate (SDS). Wildtype *E. coli* grow well in this concentration of SDS, while tolC mutants cannot<sup>37</sup>.

Tetracycline sensitive derivatives were selected on medium containing chlortetracycline and fusaric acid

-26-

(J. Bacteriol. 145:1110-1112, 1981). Tetracycline resistant carAB mutants were grown overnight in 5 mL of brain heart infusion (BHI) broth at 37°C. The cells were washed once with Minca medium and resuspended to an OD<sub>660</sub> of 0.05. Dilutions from 10<sup>-1</sup> to 10<sup>-3</sup> were made and 0.1 mL was plated per plate. Plates were incubated for 48 hours at 37°C. Large colonies were picked and streaked on BHI plates. The tetracycline sensitivity and presence of carAB mutation was confirmed.

Where noted, spontaneous rifampicin resistant mutants were selected before the tetracycline-sensitive derivatives were selected. This was done by streaking plates containing a gradient of rifampicin (from 50 to 100 µg/mL) with the carAB mutants and incubating at 37°C overnight. Colonies that grew were checked to be sure that they were still tetracycline resistant and had the carAB phenotype.

Bacterial strains were stored at -70°C in 25% glycerol and 50% BHI broth.

Vaccine strains prepared as previously described using virulent strains of *E. coli* which have been attenuated by insertion of carAB mutation from *E. coli* CGSC6181 and which are tetracycline resistant have been deposited with the American Type Culture Collection (ATCC). These strains are: (1) EC 645, ATCC Accession No. 55345, which is derived from EC 234 (serotype 078); (2) EC 644, ATCC Accession No. 55347, which is derived from EC 317 (serotype 02); and (3) EC 643, ATCC Accession No. 55349, which is derived from EC 222 (serotype 01).

Rifampicin resistant carAB mutants that are tetracycline resistant have been identified and

-27-

isolated. These strains include: (1) EC749, which is derived from EC644 (serotype 02, carAB::Tn10 in EC317); (2) EC750, which is derived from BA4 (serotype 01, carAB::Tn10 in EC222); and (3) EC769, which is derived from EC645 (serotype 078, carAB::Tn10 in EC234).

Stable tetracycline sensitive rifampicin resistant carAB mutants have been isolated and identified. These strains include: (1) BA57 (EC752), which is derived from EC234 (serotype 078); (2) BA74, which is derived from EC234 (serotype 078); (3) BA83 (EC753), which is derived from EC234 (serotype 078); (4) BA95 (EC751) which is derived from EC317 (serotype 02, ATCC Accession No. 69402); (5) BA96 (EC754), which is derived from EC317 (serotype 02); (6) BA101 (EC755), which is derived from EC317 (serotype 02); (7) BA104, which is derived from EC222 (serotype 01); (8) BA105, which is derived from EC222 (serotype 01); and (9) BA108, which is derived from EC222 (serotype 01).

Several mutants were isolated and identified as containing the fur mutation based on their over production of catechols and iron-regulated outer membrane proteins in iron-rich medium. These strains include: (1) EC655, which is derived from EC317 (serotype 02); (2) EC656, which is derived from EC222 (serotype 01); (3) EC657, which is derived from EC222 (serotype 01); (4) EC658, which is derived from EC222 (serotype 01); (5) EC662, which is derived from EC234 (serotype 078); and (6) EC663, which is derived from EC234 (serotype 078).

Several mutants were isolated and identified as containing the tolC mutation based on their tetracycline resistance and their inability to grow in LB containing 5 mg/Ml of SDS. These strains include:

-28-

- (1) BA142, which is derived from EC317 (serotype 02);
- (2) BA143, which is derived from EC317 (serotype 02);
- (3) BA144, which is derived from EC222 (serotype 01);
- (4) BA145, which is derived from EC222 (serotype 01);
- 5 (5) BA146, which is derived from EC234 (serotype 078);
- and (6) BA147, which is derived from EC234 (serotype 078).

### EXAMPLE 1

#### Oral Delivery of *E. coli* Vaccines

10 As discussed previously, attenuated bacteria would be ideal for use in a vaccine which could be delivered in drinking water. The first step in this process was to test the feasibility of vaccinating poult with *E. coli* delivered orally.

15 Duplicate groups of 8 birds were immunized orally at four weeks of age with  $5 \times 10^8$  colony forming units (CFU) of wildtype *E. coli* serotype 01 or 02 as shown in Table 1. All groups were housed in separate rooms, and four unimmunized poult were included in each room in  
20 order to determine if the *E. coli* could be transferred by shedding. After three weeks, poult were challenged with HEV<sub>A</sub> followed seven days later by  $5 \times 10^{10}$  CFU of wildtype *E. coli* 01 or 02. The results, summarized in Table 1, indicate oral immunization with either  
25 serotype was effective in inducing protection against challenge with both serotypes. Therefore, only one of these two serotypes need be included in a vaccine formulation. Further, unvaccinated sentinel animals housed in the same rooms as vaccinated poult were  
30 protected, indicating that the *E. coli* could be spread by fecal shedding. A similar experiment was conducted with serotypes 02 and 078 (Table 2). In this case, no



-29-

cross-protection was observed indicating that both of the serotypes should be present in a vaccine to provide broad-spectrum protection.

TABLE 1

5            Oral immunization of turkeys with *E. coli* serotypes 01 and 02.

Group <sup>3</sup>	Number of Poults	Immunizing Strain	Challenge Strain	Mortality	Morbidity <sup>1</sup> & Mortality
A1	8	01	01	0	1
A2	4	01	01	0	0
10    B1	8	01	02	0	0
B2	4	01	02	0	2
C1	8	02	01	0	2
C2	4	02	01	0	2
D1	8	02	02	0	0
15    D2	4	02	02	0	0
E	12	None	01	6	8
F	12	None	02	4	6
G	12	None	None	0	ND <sup>2</sup>

<sup>1</sup>Morbidity = birds with *E. coli* lesions at post mortem.

20    <sup>2</sup>ND = not done

<sup>3</sup>Groups with same letter were housed in the same room.

-30-

TABLE 2

Oral immunization of turkeys with *E. coli*  
serotypes 02 and 078.

	Group <sup>1</sup>	Number of Poults	Immunizing Strain	Challenge Strain	Mortality	Morbidity <sup>2</sup> & Mortality
5	A1	8	078	02	6	6
	A2	4	None	02	2	2
	B1	8	078	078	0	0
	B2	4	None	078	0	1
	C1	8	02	02	0	1
10	C2	4	None	02	0	0
	D1	8	02	078	2	4
	D2	4	None	078	3	3
	E	8	None	None	3	5
	F	8	None	None	0	3
15	G	12	None	None	0	0

<sup>1</sup>Groups with the same letter were housed in the same room.

<sup>2</sup>Morbidity = birds with *E. coli* lesions at post mortem.

## EXAMPLE 2

20        **Attenuation of *E. coli* serotype 01 and 078 using  
carAB mutation.**

Since oral immunization of poults with live *E. coli* appeared to be feasible, the attenuation of serotype 01 and 078 strains was initiated. Mutations  
25        in the carAB operon resulted in strains which required arginine plus uracil for growth. *E. coli* laboratory

-31-

strains carrying the drug-resistant transposon Tn10 (tetracycline resistance) insertions in this operon were used as the source of the mutations. They were transferred into serotypes 01 and 078 by transduction, and the Tn10 sequence was eliminated. Details of the procedures used were previously discussed in (2) Development of Mutants of *E. coli*. These strains were then tested for virulence using one-day-old chickens. Day old chicks are known to be susceptible to challenge with wildtype *E. coli*. The results for five *carAB* mutants are listed in Table 3. The dose of bacteria in this experiment was  $5 \times 10^4$  CFU. Since the  $LD_{50}$  of the serotype 01 strain EC 222 is  $1 \times 10^2$  CFU, the *carAB* mutation had attenuated these strains significantly. This experiment was repeated once again with results similar to those described above.

-32-

TABLE 3

Virulence of carAB mutants of serotypes 01 and 078 in a young chick model.

	Strain <sup>1</sup>	Serotype	Mortality by day							Total Mortality <sup>2</sup>
			1	2	3	4	5	6	7	
5	--	--	0	0	0	0	0	0	0	0
	EC222 (boiled)	01	0	0	0	0	0	0	0	0
	BA103	01	0	0	0	0	1	1	0	2
	BA104	01	0	2	2	0	0	0	0	4
10	BA105	01	2	0	0	1	2	0	0	5
	EC222	01	9	0	0	1	0	0	0	10
	BA74	078	0	0	0	1	0	0	0	1
	BA73	078	0	0	0	0	0	0	0	0
	EC234	078	1	0	0	2	2	3	1	9

15 <sup>1</sup>Strains with the prefix "EC" are field isolates; BA103, BA104 and BA105 are carAB mutants derived from EC222; and BA74 and BA73 are carAB mutants derived from EC234.

<sup>2</sup>Total number of birds per group = 10.

-33-

## EXAMPLE 3

**Immunization with CarAB Mutants of *E. coli*  
Serotype 078**

An experiment was conducted to determine if carAB  
5 mutant strains of *E. coli* were capable of providing  
protection from challenge with the wildtype strain.  
Turkeys were immunized orally with  $5 \times 10^9$  cfu of  
bacteria when 4 weeks old, then challenged with the  
standard challenge model of HEV<sub>A</sub> at 6 weeks of age  
10 followed by the wildtype bacteria intratracheally at 7  
weeks of age.

Birds in Group A were immunized with wildtype *E.*  
*coli* serotype 078. Group B received *E. coli* serotype  
078 with carAB mutation. Group C was immunized with *E.*  
15 *coli* serotype 078 with carAB and rifampicin mutations.  
Birds in Group D were not immunized.

Results are presented in Table 4. All birds in  
Groups A, B, and C remained healthy. No lesions were  
20 observed post mortem. Six of the 8 birds in control  
Group D died within 4 days of challenge. These results  
show that high doses of the mutant strains of *E. coli*  
serotype 078 used provided an effective protection  
against challenge with the wildtype strain.

-34-

TABLE 4

Oral immunization of turkeys with *E. coli* serotype 078.

Group	Number of Poults	Immunizing Strain	Challenge Strain	Mortality	Morbidity & Mortality
A	8	078	078	0	0
B	8	078[carAB]	078	0	0
C	8	078[carAB + Rif <sup>r</sup> ]	078	0	0
D	8	None	078	6	6

## EXAMPLE 4

Attenuation of *E. coli* serotype 01 using fur mutation.

Details of the procedures used to produce fur mutants were previously discussed in (2) Development of Mutants of *E. coli*.

Two strains (EC656 and EC657) were tested for virulence using the young chick model. The results for these two fur mutants are shown in Table 5. Newborn chicks were obtained from a local hatchery. These birds were divided into 6 groups of 20 and housed

-35-

separately. On Day 0 each group of chickens was challenged with 0.25 mL of bacteria (containing about  $10^4$  cfu or  $10^2$  cfu - see Table 5 for exact dose). The challenge was given as a subcutaneous injection of 0.25 mL. The usual precautions were taken to prevent cross contamination during administration of the challenge. The chicks were monitored for mortality at 6 hours post challenge and then every 12 hours for 7 days. After 7 days the remaining birds were sacrificed.

10 Since the mortality of the group receiving serotype 01 wildtype after 3 and 7 days was 55 and 80%, respectively ( $8 \times 10^2$  cfu's, low dose), and 100% after 3 days ( $8 \times 10^4$  cfu's, high dose), the fur mutation had attenuated these strains significantly.

-36-

TABLE 5

Virulence of fur Mutants by Serotype 01 in a Young Chick Model.

	Group <sup>1</sup>	day 0	day 1	day 2	day 3	day 4	day 5	day 6	day 7	Total Mortality	Dose <sup>2</sup>
5	BHI	1*	0	0	0	0	0	0	0	1/13	-
	EC656	0	0	0	0	0	0	0	0	0/20	low
	EC656	0	0	0	0	0	0	0	1	1/20	high
	EC657	0	0	1	0	2	0	0	0	3/20	low
	EC657	0	0	0	1	0	0	0	0	0/20	high
10	EC222	0	10	0	2	3	0	2	0	16/20	low
	EC222	0	17	1	0	0	0	0	0	20/20	high

\*This bird was not healthy before challenge.

<sup>1</sup>EC656 and EC657 are fur mutants derived from EC222 (serotype 01).

15 <sup>2</sup>Doses were as follows: EC222, low dose  $8 \times 10^2$ cfu's  
high dose  $8 \times 10^4$ cfu's  
EC656, low dose  $7 \times 10^2$ cfu's  
high dose  $7 \times 10^4$ cfu's  
EC657, low dose  $5 \times 10^2$ cfu's  
20 high dose  $5 \times 10^4$ cfu's



-37-

**EXAMPLE 5****Attenuation of *E. coli* serotype 02 using tolC mutation.**

Details of the procedures used to produce tolC mutants were previously discussed in (2) Development of Mutants of *E. coli*. Two strains (BA 142 and BA 143) were tested for virulence using the young chick model described in Example 4. A carAB mutant strain (BA95) was also used as an attenuated control. All birds received  $1 \times 10^4$  cfu's of bacteria. The results are shown in Table 6. Since the total birds affected in the group receiving serotype 02 wildtype was 50%, the tolC mutation had attenuated strain BA 142 significantly. Strain BA 143 did not appear to be attenuated in this test.

**TABLE 6**

**Virulence of tolC mutants of serotype 02 in a young chick model.**

STRAIN	MORTALITY AFTER 7 DAYS	LESIONS AFTER 7 DAYS	TOTAL BIRDS AFFECTED	PHENOTYPE
NONE	0/12	0/12	0/12	-
BA142	2/20	2/18	4/20	tolC
BA143	6/19	3/13	9/19	tolC
BA95 (EC751)	2/20	1/18	3/20	carAB
EC317	7/20	3/13	10/20	wildtype

-38-

**EXAMPLE 6****Attenuation of *E. coli* serotype 02 using *carAB* mutation.**

Details of the procedures used to produce *carAB* mutants were previously discussed in (2) Development of Mutants of *E. coli*. Strain BA95 was tested for virulence using the young chick model described in Example 4. All birds received about  $5 \times 10^4$  cfu's bacteria by subcutaneous injection. The LD<sub>50</sub> of wildtype EC317 (serotype 02) is  $6 \times 10^2$  cfu's. Results are shown in Table 7. The *carAB* mutation had attenuated strains BA95, BA96, and BA101 significantly. All three strains are tetracycline sensitive, rifampicin resistant *carAB* mutants derived from EC317 (serotype 02).

**TABLE 7**

**Virulence of *carAB* mutants of serotype 02 in a young chick model.**

CHALLENGE	MORTALITY AFTER DAY 3	MORTALITY AFTER DAY 7
NONE	0/21	0/21
WILDTYPE (EC317)	20/20	20/20
MUTANT (BA95)	1/21	3/21
MUTANT (BA96)	0/21	1/21
MUTANT (BA101)	2/21	2/21

-39-

## EXAMPLE 7

**Immunization with carAB Mutants of *E. coli* serotype 02.**

An experiment was conducted to determine if carAB  
5 mutant strains of *E. coli* were capable of providing  
protection from challenge with the wildtype strain.  
Turkeys were immunized orally with  $5 \times 10^8$  cfu of  
bacteria when 4 weeks old, then challenged with the  
standard challenge model of HEV<sub>A</sub> at 6 weeks of age to  
10 render the birds susceptible to *E. coli*. This was  
followed by challenge with  $5 \times 10^8$  cfu's of the wildtype  
bacteria in 0.2 ml, administered intratracheally at 7  
weeks of age.

Birds in Group C were immunized with wildtype *E.*  
15 *coli* serotype 02. Group B received *E. coli* serotype 02  
with carAB mutation. Birds in Group A were not  
immunized.

Results are presented in Table 8. All birds in  
Groups B and C remained healthy. No lesions were  
20 observed post mortem. Two of the 10 birds in control  
Group A died within 7 days of challenge; seven of the  
10 birds in control Group A showed morbidity and/or  
mortality. These results show that high doses of the  
mutant strains of *E. coli* serotype 02 used provided an  
25 effective protection against challenge with the  
wildtype strain.

-40-

TABLE 8

Oral immunization of Turkeys with *E. coli* serotype 02.

GROUP	VACCINE STRAIN	CHALLENGE & STRAIN	MORTALITY	MORBIDITY & MORTALITY
A	NO VACCINE	EC317	2/10	7/10
B	MUTANT (BA95)	EC317	0/9	0/9
C	WILDTYPE (EC317)	EC317	0/10	0/10

## EXAMPLE 8

Screening for stability of *E. coli* carAB mutants.

10 Preliminary testing was performed as follows:  
Sixty-eight bacterial strains with carAB mutations were grown overnight in BHI broth at 37°C with shaking. Cells were washed twice in normal saline and concentrated 10 times, then 0.1 mL of the preparation  
15 containing approximately 10<sup>9</sup> bacteria was placed on M9 medium containing 50 ng/mL nicotinic acid and incubated at 37°C for 48 hours. Duplicate plates were made for each mutant strain. Since two of the wildtype strains required nicotinic acid for growth, it was included in  
20 the minimal medium *in vitro*. The 33 strains that showed no growth on these plates, i.e., had not exhibited reversion to wildtype, were selected for secondary screening.

-41-

Secondary screening for stability of the carAB mutants was performed as follows: the 33 strains were grown in L broth (5 Ml in test tube) at 37°C overnight with shaking. The culture was diluted 10:100 mL of BHI  
5 broth and grown overnight under the same conditions. This step was repeated; then 50 mL of culture was pelleted and washed twice with normal saline. The final pellet was suspended in 1 mL of saline (a 50X concentration); then 0.1 mL of the concentrate  
10 containing approximately  $10^{11}$  cfu's was spread on each of two M9 minimal agar plates which had been supplemented with nicotinic acid. Plates were incubated for 48 hours at 37°C and examined for growth at 24 and 48 hours. Nine of the 33 strains screened  
15 showed no reversions.

Secondary screening was repeated one or two additional times on the nine strains that had no growth in the first secondary screening. Results are shown in Table 9. Reversion frequency was calculated as total  
20 number of revertants divided by the total number of cfu's plated. These data show that *E. coli* carAB mutations are stable, with reversion frequencies less than  $1 \times 10^{-9}$ .

-42-

TABLE 9

## Reversion frequencies of carAB mutants.

STRAIN	SERO-GROUP	Total No. of Revertants-Trial 1 <sup>A</sup>	Total No. of Revertants-Trial 2 <sup>A</sup>	Total No. of Revertants-Trial 3 <sup>A</sup>	Reversion Frequency <sup>B</sup>
5 BA57 (EC752)	078	0	ND	0	$<10^{-10}$
BA74	078	0	17	26	$4 \times 10^{-10}$
BA83 (EC753)	078	0	0	0	$<10^{-11}$
10 BA95 (EC751)	02	0	ND	0	$<10^{-10}$
BA96 (EC754)	02	0	0	1	$1 \times 10^{-11}$
BA101 (EC755)	02	0	2	0	$2 \times 10^{-11}$
15 BA104	01	0	54	1	$6 \times 10^{-10}$
BA105	01	0	5	16	$2 \times 10^{-10}$
BA108	01	0	3	4	$7 \times 10^{-11}$

<sup>A</sup>Total number of revertants on two plates. Each plate received  $1.8 \times 10^{10}$  cfu's.

20 <sup>B</sup>Reversion frequency is expressed as total number of revertants divided by the total number of cfu's plated in all trials.

-43-

## EXAMPLE 9

## Growth of carAB mutants in turkey sera

Sera was collected from turkeys that had not been immunized. It was stored frozen until used. The sera  
5 was heated at 56°C for 30 min to inactivate the complement. It was then centrifuged for 5 minutes in an eppendorf centrifuge to remove the particulate matter and filter sterilized.

Bacterial strains were grown overnight with  
10 shaking at 37°C in BHI (5 ml in a 15 ml test tube); then 0.1 ml of overnight culture was transferred to 5 mL of BHI in a 15 ml test tube and grown for 3 hours at 37°C with shaking. The cells were washed two times  
15 with normal saline and resuspended in 5 ml of normal saline. The absorbance at OD<sub>660</sub> nm was read to determine the cell density, and the bacteria were diluted with normal saline to give a concentration of approximately 10<sup>6</sup> cfu's/mL.

All carAB mutants used had been tested for  
20 stability as described in Example 8. The carAB mutants were derived from the wildtype strain of the same serotype. The bacterial strains used are set forth in Table 10.

The bacteria were grown in turkey sera using the  
25 following procedures: 0.2 ml of the diluted cell suspension was added to 0.4 ml of sera and incubated at 37°C. Samples were taken at 0, 1.5, 3, and 6 hours of incubation. Dilutions were made in normal saline, and 0.025 ml volumes of several dilutions were spotted onto  
30 a BHI agar plate. The number of colonies was counted after 18 hours incubation at 37°C.

-44-

All strains tested grew in normal serum at approximately the same rate. These data indicate that carAB mutants are capable of growth in normal serum. This is unexpected in view of previous work which teaches that pyrimidine levels in serum may be limiting<sup>41</sup>.

TABLE 10

Bacterial strains grown in turkey sera.

STRAIN	SEROGROUP	PHENOTYPE
EC222	01	WILDTYPE
EC234	078	WILDTYPE
EC317	02	WILDTYPE
BA74	078	carAB mutant
BA83 (EC753)	078	carAB mutant
BA95 (EC751)	02	carAB mutant
BA96 (EC754)	02	carAB mutant
BA104	01	carAB mutant
BA105	01	carAB mutant

## EXAMPLE 10

Mapping Tn10 carAB junctions.

Localization of Tn10 by southern blot analysis was performed as follows: chromosomal DNA was isolated from EC317, EC222, EC234, EC749, EC750, and EC769 using the method of Stauffer et al. (Gene 14:63-72, 1981).



-45-

Plasmid pLLK12 was digested with *PvuII* and the fragments separated on agarose gels. DNA fragments were isolated from the agarose gel using GeneClean Kit (Bio 101 Inc. Box 2284, La Jolla, California, U.S.A.) according to the manufacturer's instructions. Fragments B & C were not well resolved on the gel so were used to produce a single probe. The probe specific for Tn10 was produced by digesting a plasmid containing Tn10 with *BglII*. DNA was labelled using the Oligolabelling kit (Pharmacia LKB Biotechnology) with [ $\alpha$ -<sup>32</sup>P]dCTP. Southern blot analysis was done according to standard techniques (Sambrook et al., 1989).

Tn10 was found to be inserted in the *PvuII*-E fragment of the *carAB* operon. The southern blot analysis of the *PvuII* digests of chromosomal DNA from insertion mutant EC749 produced an identical pattern when the *BglII* fragment of Tn10 containing the tetracycline resistance gene or the *PvuII*E fragment of the *carAB* operon from pLLK12 was used as a probe. Probing chromosomal digests with either the fragment D or a mixture of fragments B & C produced dramatically different patterns.

The transposon appeared to be inserted at the same site in all three strains where the *carAB*::Tn10 was transferred to the cells by transduction with P1. However, it is evident that there is restriction length polymorphism of the *PvuII* digested *carAB* operon in the wildtype strains EC222, EC317, and EC234, as a diversity of patterns was observed when the *PvuII* digested chromosomal DNA was probed with the *carAB* fragment E.

The *carAB* operon was cloned as follows: DNA from EC750 was used. This strain was produced by

-46-

transducing the *carAB* operon marked with Tn10 from EC322 into EC222 as described earlier.

Chromosomal DNA was isolated from EC750 using the method of Stauffer et al. (Gene 14:63-72, 1981). The  
5 chromosomal DNA was digested with *PvuII* and ligated into the *HincII* site of pUC19 using the technique of Sambrook et al<sup>27</sup>.

Subcloning efficiency competent *E. coli* DH5 $\alpha$  (Gibco BRL Life Technologies, Inc., Gaithersburg,  
10 Maryland, U.S.A.) was transformed using 1-3 microliters ( $\mu$ L) of the ligation mix according to the manufacturer's instructions, and transformants were selected on plates containing 50  $\mu$ g ampicillin. Clones that were also resistant to tetracycline were selected  
15 by replica plating on plates containing tetracycline. A plasmid with the reading frame of the *carAB* operon in the same orientation as the vector (pJK931) was selected for further study. The strain containing pJK931 is EC745.

20 Sequence analysis was performed as follows: using synthetic primers the sequence for both strands of DNA was obtained. Since the sequence of both Tn10 and the *carAB* operon are known<sup>18,42,43</sup> it was possible to determine the exact site of insertion of Tn10 into the operon.  
25 The transposon Tn10 was inserted into the operon at the 5'-GGCTTGCC-3', nucleotides 3139 to 3147 of *carAB*<sup>18</sup>. The Tn10 insertion involves recognition, cleavage, and duplication of a specific nine base pair (bp) target consensus sequence, 5'-NGCTNAGCN-3'<sup>44</sup>. Comparison of  
30 the *carAB* target site with the putative consensus sequence reveals a difference only at position 6 where A is replaced by T. However, the six consensus base

-47-

pairs comprising the interrupted three bp inverted symmetry is preserved.

Modification of the above-described modes of carrying out various embodiments of this invention will  
5 be apparent to those skilled in the art following the teachings of this invention as set forth herein. The examples described above are not limiting, but are merely exemplary of this invention, the scope of which is defined by the following claims.

-48-

## WHAT IS CLAIMED IS:

1. A vaccine strain of a pathogenic bacteria comprising at least one mutation selected from the group consisting of a pyrimidine pathway mutation, an iron metabolism mutation and a colicin transport mutation, said mutation providing attenuation of the virulence of said bacteria.
2. A vaccine strain as in Claim 1 wherein the vaccine strain is a live vaccine strain.
3. A vaccine strain as in Claim 1 wherein said mutation is selected from the group consisting of *carAB*, *fur* and *tolC*.
4. A vaccine strain as in Claim 1 comprising at least two of said mutations.
5. A vaccine strain as in Claim 1 wherein said strain has a reversion frequency less than about  $10^{-7}$ .
6. A vaccine strain as in Claim 1 wherein said pathogenic bacteria comprises an extracellular pathogenic bacteria.
7. A vaccine strain as in Claim 1 wherein said pathogenic bacteria comprises *E. coli*.
8. A vaccine strain as in Claim 7 wherein said *E. coli* is serotype 01, 02 or 078.
9. A vaccine strain as in Claim 8 wherein said vaccine strain is selected from the group consisting of serotype 01[*carAB*], serotype 02[*carAB*] serotype 078[*carAB*], serotype 01[*fur*], serotype 02[*fur*],

-49-

serotype 078[fur], serotype 01[tolC], serotype  
02[tolC], serotype 078[tolC], *E. coli* strain EC645 ATCC  
Accession No. 55345, *E. coli* strain EC644 ATCC  
Accession No. 55347, *E. coli* strain EC643 ATCC  
5 Accession No. 55349, and *E. coli* strain EC751 ATCC  
Accession No. 69402.

10. A method of preparing a vaccine strain of a  
pathogenic bacteria comprising:

- (a) producing at least one mutation selected  
10 from the group consisting of a pyrimidine pathway  
mutation, an iron metabolism mutation, and a colicin  
transport mutation, in a virulent strain of said  
pathogenic bacteria to provide an attenuated organism;  
(b) isolating the attenuated organism which  
15 contains said at least one mutation; and  
(c) using said isolated organism as a  
vaccine strain.

11. The method of Claim 10 wherein said mutation  
is selected from the group consisting of *carAB*, *fur* and  
20 *tolC*.

12. The method of Claim 10 wherein said  
attenuated organism comprises at least two of said  
mutations.

13. The method of Claim 10 wherein said vaccine  
25 strain has a reversion frequency of less than about  
 $10^{-7}$ .

14. The method of Claim 10 comprising selecting  
an attenuating mutation associated with a marker gene.

15. The method of Claim 14 wherein said marker  
30 gene is an antibiotic resistance gene.

-50-

16. The method of Claim 15, further comprising isolating *E. coli* mutants which revert to antibiotic sensitivity.

17. A vaccine composition comprising at least one vaccine strain of a pathogenic bacteria having at least one attenuating mutation selected from the group consisting of a pyrimidine pathway mutation, an iron metabolism mutation, and a colicin transport mutation.

18. The composition of Claim 17 wherein said mutation is selected from the group consisting of *carAB*, *fur*, and *tolC*.

19. The composition of Claim 17 wherein said vaccine strain is a live vaccine strain.

20. The composition of Claim 17 wherein said vaccine strain comprises at least two of said mutations.

21. The composition of Claim 17 wherein said at least one vaccine strain comprises *E. coli*.

22. The composition of Claim 21 which comprises at least two vaccine strains of *E. coli*.

23. The composition of Claim 22 wherein each of said vaccine strains is selected from the group consisting of serotype 078[*carAB*], serotype 01[*carAB*], serotype 02[*carAB*], serotype 078[*fur*], serotype 01[*fur*], serotype 02[*fur*], serotype 078[*tolC*], serotype 01[*tolC*], and serotype 02[*tolC*].

24. A method of preventing a bacterial disease in an animal comprising administering to said animal an

-51-

effective amount of at least one vaccine strain of a pathogenic bacteria which causes said disease wherein said vaccine strain comprises at least one mutation selected from the group consisting of a pyrimidine pathway mutation, an iron metabolism mutation and a colicin transport mutation.

25. The method of Claim 24 wherein said mutation is selected from the group consisting of *carAB*, *fur* and *tolC*.

26. The method of Claim 24 wherein said disease comprises colisepticemia and said pathogenic bacteria comprises *E. coli*.

27. The method of Claim 24 wherein said administration is oral.

28. The method of Claim 24 wherein said administration is to an avian species.

29. The method of Claim 24 wherein at least two vaccine strains are administered.

30. The method of Claim 29 wherein each of said vaccine strains is selected from the group consisting of *E. coli* serotype 078[*carAB*], *E. coli* serotype 01[*carAB*], *E. coli* serotype 02[*carAB*], *E. coli* serotype 078[*fur*], *E. coli* serotype 01[*fur*], *E. coli* serotype 02[*fur*], *E. coli* serotype 078[*tolC*], *E. coli* serotype 01[*tolC*], and *E. coli* serotype 02[*tolC*].

Applicant's or agent's file  
reference number

47998-2

International application No.

PCT/CA/ 93/00365

# INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 26, line 25-26

## B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet



Name of depositary institution

American Type Culture Collection

Address of depositary institution (including postal code and country)

12301 Parklawn Drive  
Rockville, Maryland 20852  
United States of America

Date of deposit

26 August 1992 (26.08.92)

Accession Number

55345

## C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet



## D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

## E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only



This sheet was received with the international application

Authorized officer

For International Bureau use only



This sheet was received by the International Bureau on:

21 SEPTEMBER 1993

Authorized officer





Applicant's or agent's file reference number	47998-2	International application No.	PCT/CA/ 93/00365
--	---------	-------------------------------	------------------

# INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>26</u> , line <u>27-28</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country)  12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 26 August 1992 (26.08.92)	Accession Number 55347
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only
<input checked="" type="checkbox"/> This sheet was received with the international application
Authorized officer 

For International Bureau use only
<input type="checkbox"/> This sheet was received by the International Bureau on:
21 SEPTEMBER 1993
Authorized officer 

Applicant's or agent's file  
reference number



47998-2

International application No.

PCT/GAI 93/00365

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>26</u> , line <u>28-30</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 26 August 1992 (26.08.92)	Accession Number 55349
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")     	
<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application  Authorized officer	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on: 21 SEPTEMBER 1993 Authorized officer 

Applicant's or agent's file  
reference number 47998-2

International application No. **PCT/CA/ 93/00365**

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 27, line 11-13

### B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution

American Type Culture Collection

Address of depositary institution (including postal code and country)

12301 Parklawn Drive  
Rockville, Maryland 20852  
United States of America

Date of deposit

26 August 1993 (26.08.93)

Accession Number

69402

### C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet ☐

### D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

### E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

☒ This sheet was received with the international application

Authorized officer

For International Bureau use only

☐ This sheet was received by the International Bureau on:

Authorized officer

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/CA 93/00365

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61K39/108

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,91 06317 (WASHINGTON UNIVERSITY) 16 May 1991 see page 10, line 5 - page 11, line 28 ---	1,2,10, 17,19
Y	FR,A,2 282 908 (CANADIAN PATENTS AND DEVELOPMENT LIMITED) 26 March 1976 see page 1, line 1 - page 4, line 20 ---	1,2,10, 17,19
Y	EP,A,0 389 347 (RHONE MERIEUX) 26 September 1990 see page 1, line 1 - page 6, line 30 ---	1,2,10, 17,19
Y	WO,A,92 12732 (REGENTS OF THE UNIVERSITY OF MINNESOTA) 6 August 1992 cited in the application see page 5 -----	1,2,10, 17,19

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

- \* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* "&" document member of the same patent family

Date of the actual completion of the international search

30 November 1993

Date of mailing of the international search report

21 -12- 1993

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Rempp, G

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA93/00365

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 24-30 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No.

PCT/CA 93/00365

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9106317	16-05-91	AU-A- 6737190 EP-A- 0500699 JP-T- 5504331	31-05-91 02-09-92 08-07-93
FR-A-2282908	26-03-76	GB-A- 1472624 AU-A- 8440975 BE-A- 832967 DE-A- 2538994 JP-A- 51051514 NL-A- 7510120	04-05-77 03-03-77 31-12-75 16-06-76 07-05-76 04-03-76
EP-A-0389347	26-09-90	FR-A- 2644346 AU-A- 5415390 CA-A- 2029906 WO-A- 9011349 JP-A- 3143388	21-09-90 22-10-90 21-09-90 04-10-90 18-06-91
WO-A-9212732	06-08-92	AU-A- 1229492	27-08-92